drugset / Trial / NCT03621046

Use of Low-dose Zolpidem in Parkinson's Disease

NCT03621046

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will evaluate the motor and cognitive benefits of low-dose zolpidem in Parkinson's.

Timeline

Start
2018-08-20
Primary completion
2019-12-31
Completion
2020-01-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Zolpidem Small molecule 5 mg Oral

Indications